Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jun;14(3):831-835.
doi: 10.1007/s12328-021-01372-z. Epub 2021 Mar 2.

Beta-catenin-activated hepatocellular adenoma in a male

Ryosuke Ishida  1 , Yoshihiko Yano  2 , Atsushi Yamamoto  1 , Eiichiro Yasutomi  1 , Yuri Hatazawa  1 , Hiroki Hayashi  1 , Yuuki Shiomi  1 , Hidetoshi Gon  3 , Satoshi Omiya  3 , Maki Kanzawa  4 , Tomoo Itoh  4 , Yoshihide Ueda  1 , Yuzo Kodama  1
Affiliations
Case Reports

Beta-catenin-activated hepatocellular adenoma in a male

Ryosuke Ishida et al. Clin J Gastroenterol. 2021 Jun.

Abstract

Beta-catenin-activated hepatocellular adenoma is potentially malignant and warrants careful follow-up and surgical resection. Here, we report a 48-year-old man in whom a 55 mm single liver tumor was incidentally detected in the S1 segment. Contrast-enhanced computed tomography scans showed no enhancement in the early phase and a slight defection in the late phase. The tumor was enhanced hyperintensity in the hepatobiliary phase on Gd-ethoxybenzyl-diethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging. The histologic features of ultrasound-guided fine-needle aspiration biopsy indicated hepatocellular adenoma, and the tumor was immunohistochemically positive for glutamine synthetase and β-catenin. Considering the risk of malignant transformation, he underwent laparoscopic-assisted partial liver resection. The resected tumor did not contain any malignant lesions. This case indicates that aspiration needle biopsy and immunohistochemistry were useful for histological diagnosis and treatment decisions based on the molecular definition of hepatocellular adenoma.

Keywords: Fine needle aspiration biopsy; Glutamine synthetase; Hepatocellular adenoma; Malignant transformation; β-Catenin-activated hepatocellular adenoma.

PubMed Disclaimer

References

    1. Agrawal S, Agarwal S, Arnason T, et al. Management of hepatocellular adenoma: recent advances. Clin Gastroenterol Hepatol. 2015;13:1221–30. - DOI
    1. Bioulac-Sage P, Laumonier H, Couchy G, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology. 2009;50:481–9. - DOI
    1. Nault JC, Couchy G, Balabaud C, et al. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology. 2017;152:880–94. - DOI
    1. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43:515–24. - DOI
    1. Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumors of the digestive system; World Health Organization of Tumors. 4th ed. Lyon: IARC; 2010. p. 198–204.

Publication types

LinkOut - more resources